

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM538529

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	Notice of Grant of Security Interest in Patents and Trademarks		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Indivior UK Limited	FORMERLY RB Pharmaceuticals Limited	08/27/2019	Limited Company: ENGLAND AND WALES
RECEIVING PARTY DATA			
Name:	Morgan Stanley Senior Funding Inc., as Collateral Agent		
Street Address:	1300 Thames Street, 4th Floor		
City:	Baltimore		
State/Country:	MARYLAND		
Postal Code:	21231		
Entity Type:	Corporation: DELAWARE		
PROPERTY NUMBERS Total: 12			
Property Type	Number	Word Mark	
Registration Number:	5715849	PERSERIS	
Registration Number:	5525874	INSUPPORT	
Registration Number:	5536794	INSUPPORT	
Registration Number:	5525875	INSUPPORT	
Registration Number:	5676163	INSUPPORT	
Registration Number:	5667271	INSUPPORT	
Registration Number:	5624276	INSUPPORT	
Registration Number:	5624275	INSUPPORT	
Registration Number:	5586819	SUBLOCADE	
Registration Number:	5587022	SUBLOCADE	
Registration Number:	5587023	SUBLOCADE	
Registration Number:	5000259		
CORRESPONDENCE DATA			
Fax Number:			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	2136207848		
Email:	iprecordations@whitecase.com		
Correspondent Name:	Justine Lu/White & Case LLP		

CH \$315.00 5715849

TRADEMARK

Address Line 1: 555 South Flower Street, 2700
Address Line 4: Los Angeles, CALIFORNIA 90071

ATTORNEY DOCKET NUMBER: 1130558-0147-S216

NAME OF SUBMITTER: Justine Lu

SIGNATURE: /Justine Lu/

DATE SIGNED: 08/28/2019

Total Attachments: 11

source=Indivior - IP Security Agreement (August 2019)#page1.tif
source=Indivior - IP Security Agreement (August 2019)#page2.tif
source=Indivior - IP Security Agreement (August 2019)#page3.tif
source=Indivior - IP Security Agreement (August 2019)#page4.tif
source=Indivior - IP Security Agreement (August 2019)#page5.tif
source=Indivior - IP Security Agreement (August 2019)#page6.tif
source=Indivior - IP Security Agreement (August 2019)#page7.tif
source=Indivior - IP Security Agreement (August 2019)#page8.tif
source=Indivior - IP Security Agreement (August 2019)#page9.tif
source=Indivior - IP Security Agreement (August 2019)#page10.tif
source=Indivior - IP Security Agreement (August 2019)#page11.tif

Notice of Grant of Security Interest in Patents and Trademarks

NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS AND TRADEMARKS, dated as of August 27, 2019 (this “**Agreement**”), made by Indivior UK Limited (formerly known as RB Pharmaceuticals Limited), a limited company organized under the laws of England and Wales, (the “**Pledgor**”), in favor of Morgan Stanley Senior Funding, Inc., as Collateral Agent (as defined below).

Reference is made to the U.S. Security Agreement, dated as of December 23, 2014 (as amended, restated, supplemented and/or otherwise modified from time to time, the “**Security Agreement**”), by and among Indivior Finance (2014) LLC, a limited liability company organized under the laws of Delaware (the “**U.S. Co-Borrower**” or the “**U.S. Term Borrower**”), RBP Global Holdings Limited, a limited company organized under the laws of England and Wales (the “**Borrower Representative**” or the “**Revolver Borrower**”, and together with the U.S. Term Borrower, collectively referred to herein as the “**Borrowers**” and each a “**Borrower**”), Indivior US Holdings Inc. (formerly known as RBP US Holdings Inc.), a corporation organized under the laws of Delaware, Indivior Finance LLC (formerly known as RBP Finance LLC), a limited liability company organized under the laws of Delaware, Indivior Inc. (formerly known as Reckitt Benckiser Pharmaceuticals Inc.), a corporation organized under the laws of Delaware, Indivior Solutions Inc. (formerly known as Reckitt Benckiser Pharmaceuticals Solutions Inc.), a corporation organized under the laws of Delaware, each subsidiary of a Borrower from time to time party thereto, and Morgan Stanley Senior Funding, Inc., as collateral agent for the Secured Parties referred to therein (together with its successors and assigns in such capacity, the “**Collateral Agent**”).

The parties hereto agree as follows:

SECTION 1. Terms. Capitalized terms used in this Agreement and not otherwise defined herein have the meanings specified in the Security Agreement. The rules of construction specified in Section 1.01(b) of the Security Agreement also apply to this Agreement.

SECTION 2. Grant of Security Interest. As security for the payment and performance, as applicable, in full of the Secured Obligations, the Pledgor pursuant to the Security Agreement did, and hereby does, grant to the Collateral Agent, its successors and permitted assigns, for the benefit of the Secured Parties, a continuing security interest in all of such Pledgor’s right, title and interest in, to and under any and all of the following assets now owned or at any time hereafter acquired by such Pledgor or in which such Pledgor now has or at any time in the future may acquire any right, title or interest : (a) all U.S. registered and applied for Patents, including those listed on Schedule I (collectively, but excluding any Excluded Assets, the “**Patent Collateral**”); and (b) all U.S. registered and applied for Trademarks, including those listed on Schedule II (collectively, but excluding any Excluded Assets, the “**Trademark Collateral**”);

provided, however, that the foregoing grant of security interest will not cover any intent-to-use (or similar) Trademark application prior to the filing and acceptance of a "Statement of Use", "Amendment to Allege Use" or similar filing with respect thereto, only to the extent, if any, that, and solely during the period in which, if any, the grant of a security interest therein may impair the validity or enforceability of such intent-to-use Trademark application under applicable law.

SECTION 3. Security Agreement. The security interests granted to the Collateral Agent herein are granted in furtherance, and not in limitation of, the security interests granted to the Collateral Agent pursuant to the Security Agreement. Each Pledgor hereby acknowledges and affirms that the rights and remedies of the Collateral Agent with respect to the Patent Collateral and the Trademark Collateral are more fully set forth in the Security Agreement, the terms and provisions of which are hereby incorporated herein by reference as if fully set forth herein. In the event of any conflict between the terms of this Agreement and the Security Agreement, the terms of the Security Agreement shall govern.

SECTION 4. Counterparts. This Agreement may be executed in two or more counterparts, each of which shall constitute an original but all of which when taken together shall constitute but one contract. Delivery of an executed counterpart to this Agreement by facsimile or other electronic transmission (including ".pdf" or ".tif") shall be as effective as delivery of a manually signed original.


SECTION 5. Governing Law. THIS AGREEMENT AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO THIS AGREEMENT, WHETHER IN TORT, CONTRACT (AT LAW OR IN EQUITY) OR OTHERWISE, SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.

SECTION 6. Termination. This Agreement is made to secure the payment of the Secured Obligations. This Agreement and the security interest granted hereby shall terminate with respect to all of the Pledgor's Secured Obligations and any Lien arising therefrom shall be automatically released upon termination of the Security Agreement or release of the Pledgor's Secured Obligations thereunder or as otherwise provided in the Security Agreement. The Collateral Agent shall, in connection with any termination or release herein or under the Security Agreement, execute and deliver to the Pledgor as the Pledgor may request, an instrument in writing releasing the security interest in the Patent Collateral and the Trademark Collateral specified in this Agreement, in each case, in accordance with the requirements of the Security Agreement.

[Signature Pages Follow]


IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the day and year first above written.

Indivior UK Limited

By: 
Name: Brent Harwood
Title: VP, Group Treasurer

ACCEPTED AND AGREED:

MORGAN STANLEY SENIOR FUNDING, INC.
as Collateral Agent

By: 

Name: Ethan Plater
Title: Vice President

Schedule I

U.S. Patent Applications Owned by

Indivior UK Limited (formerly known as RB Pharmaceuticals Limited)

Title	App. No.	App. Date	Reg. No.	Reg. Date	Owner
INJECTABLE COMPOSITION COMPRISING BUPRENORPHINE	15/334,000	10/25/2016	9782402	10/10/2017	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
INJECTABLE FLOWABLE COMPOSITION COMPRISING BUPRENORPHINE	15/623,191	06/14/2017	9827241	11/28/2017	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
SUSTAINED-RELEASE BUPRENORPHINE FORMULATIONS	15/847,548	12/19/2017	--	--	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
BUPRENORPHINE DOSING REGIMENS	15/523,986	05/03/2017	--	--	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
INJECTABLE FLOWABLE COMPOSITION COMPRISING BUPRENORPHINE	15/820,048	11/21/2017	--	--	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
INJECTABLE FLOWABLE COMPOSITION COMPRISING BUPRENORPHINE	15/857,507	12/28/2017	10,198,218	02/05/2019	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
SUSTAINED DELIVERY FORMULATIONS OF RISPERIDONE COMPOUND	15/858,525	12/29/2017	10,376,590	8/13/2019	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
INTRANASAL NALOXONE COMPOSITIONS AND METHODS OF MAKING AND USING SAME	15/889,857	02/06/2018	--	--	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
INTRANASAL NALOXONE	16/110,440	8/23/2018	--	--	Indivior UK Limited (f/k/a

COMPOSITIONS AND METHODS OF MAKING AND USING SAME					RB Pharmaceuticals Limited)
INTRANASAL NALOXONE COMPOSITIONS AND METHODS OF MAKING AND USING SAME	16/379,337	4/9/2019	--	--	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
Pharmaceutical Films	62/611,928	12/29/2017	--	--	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
METHODS TO TREAT OPIOID USE DISORDER	62/521,121	06/16/2017	--	--	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
METHODS TO TREAT OPIOID DISORDER	62/572,331	10/13/2017	--	--	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
Methods to Treat Opioid Use Disorder	62/572,996	10/16/2017	--	--	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
Methods to Treat Opioid Use Disorder	62/598,338	12/13/2017	--	--	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
Methods to Treat Opioid Use Disorder	62/632,995	02/20/2018	--	--	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
DOPAMINE D3 RECEPTOR ANTAGONISTS	15/975,466	05/09/2018	10,239,870	03/26/2019	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS	16/261,206	01/29/2019	--	--	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
DOPAMINE D3 RECEPTOR	15/522,863	10/30/2015	10,000,477	06/19/2018	Indivior UK Limited (f/k/a

ANTAGONIST COMPOUNDS					RB Pharmaceuticals Limited)
DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY	16/292,110	03/04/2019	--	--	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
SUBSTITUTED HEXAHYDROPYRROLO [3,4-B] PYRROLES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE	15/750,128	02/02/2018	10,273,244	04/30/2019	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
METHODS FOR TREATING SCHIZOPHRENIA	16/101,298	08/10/2018	--	--	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
SUSTAINED-RELEASE BUPRENORPHINE SOLUTIONS	16/016,186	06/22/2018	--	--	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
SUSTAINED-RELEASE BUPRENORPHINE SOLUTIONS	15/125,052	03/09/2015	10,022,367	07/17/2018	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
DEHYDRATED HYDROGEL INCLUSION COMPLEX	15/295,630	10/17/2016	10,149,912	12/11/2018	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
METHODS TO TREAT OPIOID USE DISORDER	16/016,250	06/22/2018	--	--	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
SUSTAINED RELEASE SMALL MOLECULE DRUG FORMULATION	15/422,626	02/02/2017	10,058,554	08/28/2018	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
SUSTAINED RELEASE SMALL MOLECULE DRUG FORMULATION	16/044,259	07/24/2018	--	--	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)




SYRINGE SYSTEM	16/041,170	07/20/2018	--	--	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
BUPRENORPHINE TO TREAT RESPIRATORY DEPRESSION	62/744,530	10/11/2018	--	--	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
BUPRENORPHINE TO TREAT RESPIRATORY DEPRESSION	62/795,258	01/22/2019	--	--	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
BUPRENORPHINE TO TREAT RESPIRATORY DEPRESSION	62/817,136	03/12/2019	--	--	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
METHODS FOR TREATING SCHIZOPHRENIA	62/795,260	01/22/2019	--	--	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
Psychiatric Treatment for Patients with Gene Polymorphisms	62/366,768	07/26/2016			Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
SUSTAINED RELEASE SMALL MOLECULE DRUG FORMULATION	16/511,210	7/15/2019	--	--	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
SUSTAINED DELIVERY FORMULATIONS OF RISPERIDONE COMPOUND	16/509,287	7/11/2019	--	--	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
SUBLINGUAL AND BUCCAL FILM COMPOSITIONS	16/439,530	6/12/2019	--	--	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
SYRINGE SYSTEM	62/685,786	6/15/2018	--	--	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)




METHODS TO TREAT OPIOID USE DISORDER	62/680,935	6/5/2018	--	--	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
METHODS FOR DETECTING NALOXONE DEGRADATION PRODUCTS	62/657,528	4/13/2018	--	--	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
METHODS TO TREAT OPIOID USE DISORDER	62/656,216	4/11/2018	--	--	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
SUBLINGUAL AND BUCCAL FILM COMPOSITIONS	15/483,769	4/10/2017			Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
QUANTIFICATION OF DRUGS IN BIOLOGICAL SAMPLES	15/772,457	11/2/2016	--	--	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING MORPHOLINE MOIETY	15/767,328	10/13/2016	--	--	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
PSYCHIATRIC TREATMENT FOR PATIENTS WITH GENE POLYMORPHISMS	15/763,777	9/29/2016	--	--	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
SUSTAINED RELEASE SMALL MOLECULE DRUG FORMULATION	14/701,173	4/30/2015	9,597,402	3/21/2017	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)

Schedule II

U.S. Trademark Applications Owned by

Indivior UK Limited (formerly known as RB Pharmaceuticals Limited)

Title	App. No.	App. Date	Reg. No.	Reg. Date	Owner
PERSERIS	86/892,714	02/01/2016	5715849	04/02/2019	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
INSUPPORT	87/444,993	05/10/2017	5525874	07/24/2018	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
INSUPPORT	87/445,003	05/10/2017	5536794	08/07/2018	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
INSUPPORT	87/445,011	05/10/2017	5525875	07/24/2018	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
INSUPPORT	87/631,683	10/03/2017	5676163	02/12/2019	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
inSupport (Stylized/Design) 	87/631,701	10/03/2017	5667271	01/29/2019	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
inSupport (Stylized/Design) 	87/978,087	10/03/2017	5624276	12/04/2018	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
inSupport (Stylized/Design) 	87/978,086	10/03/2017	5624275	12/04/2018	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)

SUBLOCADE	87/210,480	10/20/2016	5586819	10/16/2018	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
Sublocade (Stylized/Design) 	87/328,982	02/08/2017	5587022	10/16/2018	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
Sublocade (Stylized/Design) 	87/329,052	02/08/2017	5587023	10/16/2018	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)
	86/979,317	5/22/2015	5000259	7/12/2016	Indivior UK Limited (f/k/a RB Pharmaceuticals Limited)